| 13.05 08:30 | dpa-AFX: GNW-Adhoc: Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor |
| 03.04 22:00 | dpa-AFX: GNW-Adhoc: Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F |
| 28.03 08:00 | dpa-AFX: GNW-Adhoc: Inventiva announces the nomination of Andre Turenne as Director |
| 27.03 21:00 | dpa-AFX: GNW-Adhoc: Inventiva reports its 2023 full-year results |
| 22.03 21:00 | dpa-AFX: GNW-Adhoc: Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results |
| 18.03 21:00 | dpa-AFX: GNW-Adhoc: Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D |
| 07.03 22:00 | dpa-AFX: GNW-Adhoc: Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed |
| 15.02 22:35 | dpa-AFX: GNW-Adhoc: Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3 |
| 24.01 22:15 | dpa-AFX: GNW-Adhoc: Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux |
| 10.01 22:00 | dpa-AFX: GNW-Adhoc: Inventiva draws down the second tranche of ?25 million under existing Finance Contract with the European Investment Bank |
| 20.12 22:00 | dpa-AFX: GNW-Adhoc: Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program |
| 04.12 22:05 | dpa-AFX: GNW-Adhoc: Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH |
| 21.11 22:00 | dpa-AFX: GNW-Adhoc: Inventiva reports 2023 Third Quarter Financial Information¹ |
| 06.11 22:00 | dpa-AFX: GNW-Adhoc: Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023 |
| 28.09 22:00 | dpa-AFX: GNW-Adhoc: Inventiva reports its 2023 first-half financial results and provides a corporate update |
| 20.09 22:00 | dpa-AFX: GNW-Adhoc: Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea |
| 31.08 07:30 | dpa-AFX: GNW-Adhoc: Inventiva announces a financing of approximately ?35.7 million from new and existing investors, consisting of a ?30.6 million reserved capital increase and a ?5.1 million issuance of royalty certificates |
| 27.07 22:33 | dpa-AFX: GNW-Adhoc: Correction: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update |
| 27.07 22:00 | dpa-AFX: GNW-Adhoc: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update |
| 24.06 08:00 | dpa-AFX: GNW-Adhoc: Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association |
|
|
